195 related articles for article (PubMed ID: 24362550)
1. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Zeidner JF; Karp JE; Blackford AL; Smith BD; Gojo I; Gore SD; Levis MJ; Carraway HE; Greer JM; Ivy SP; Pratz KW; McDevitt MA
Haematologica; 2014 Apr; 99(4):672-8. PubMed ID: 24362550
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Karp JE; Giles FJ; Gojo I; Morris L; Greer J; Johnson B; Thein M; Sznol M; Low J
Leuk Res; 2008 Jan; 32(1):71-7. PubMed ID: 17640728
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ; Christos P; Sparano JA; Matulich D; Kaubish A; Siegel A; Sung M; Ward MM; Hamel N; Espinoza-Delgado I; Yen Y; Lane ME
Cancer Chemother Pharmacol; 2011 Aug; 68(2):379-88. PubMed ID: 20981545
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Gojo I; Tidwell ML; Greer J; Takebe N; Seiter K; Pochron MF; Johnson B; Sznol M; Karp JE
Leuk Res; 2007 Sep; 31(9):1165-73. PubMed ID: 17324462
[TBL] [Abstract][Full Text] [Related]
6. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials referral resource. Current clinical trials investigating 3-AP.
Low JA; Schoenfeldt M
Oncology (Williston Park); 2005 Mar; 19(3):354, 357-8. PubMed ID: 15828551
[No Abstract] [Full Text] [Related]
8. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
Kunos CA; Chu E; Beumer JH; Sznol M; Ivy SP
Cancer Chemother Pharmacol; 2017 Jan; 79(1):201-207. PubMed ID: 27878356
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
Knox JJ; Hotte SJ; Kollmannsberger C; Winquist E; Fisher B; Eisenhauer EA
Invest New Drugs; 2007 Oct; 25(5):471-7. PubMed ID: 17393073
[TBL] [Abstract][Full Text] [Related]
10. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Giles FJ; Fracasso PM; Kantarjian HM; Cortes JE; Brown RA; Verstovsek S; Alvarado Y; Thomas DA; Faderl S; Garcia-Manero G; Wright LP; Samson T; Cahill A; Lambert P; Plunkett W; Sznol M; DiPersio JF; Gandhi V
Leuk Res; 2003 Dec; 27(12):1077-83. PubMed ID: 12921943
[TBL] [Abstract][Full Text] [Related]
12. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Nutting CM; van Herpen CM; Miah AB; Bhide SA; Machiels JP; Buter J; Kelly C; de Raucourt D; Harrington KJ
Ann Oncol; 2009 Jul; 20(7):1275-9. PubMed ID: 19246715
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Kunos C; Radivoyevitch T; Abdul-Karim FW; Fanning J; Abulafia O; Bonebrake AJ; Usha L
J Transl Med; 2012 Apr; 10():79. PubMed ID: 22541066
[TBL] [Abstract][Full Text] [Related]
16. Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry.
Feng Y; Kunos CA; Xu Y
Biomed Chromatogr; 2015 Sep; 29(9):1380-7. PubMed ID: 25677991
[TBL] [Abstract][Full Text] [Related]
17. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.
Rambaldi A; Grassi A; Masciulli A; Boschini C; Micò MC; Busca A; Bruno B; Cavattoni I; Santarone S; Raimondi R; Montanari M; Milone G; Chiusolo P; Pastore D; Guidi S; Patriarca F; Risitano AM; Saporiti G; Pini M; Terruzzi E; Arcese W; Marotta G; Carella AM; Nagler A; Russo D; Corradini P; Alessandrino EP; Torelli GF; Scimè R; Mordini N; Oldani E; Marfisi RM; Bacigalupo A; Bosi A
Lancet Oncol; 2015 Nov; 16(15):1525-1536. PubMed ID: 26429297
[TBL] [Abstract][Full Text] [Related]
18. LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
Matsumoto J; Kiesel BF; Parise RA; Guo J; Taylor S; Huang M; Eiseman JL; Ivy SP; Kunos C; Chu E; Beumer JH
J Pharm Biomed Anal; 2017 Nov; 146():154-160. PubMed ID: 28881312
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.
Kunos CA; Waggoner S; von Gruenigen V; Eldermire E; Pink J; Dowlati A; Kinsella TJ
Clin Cancer Res; 2010 Feb; 16(4):1298-306. PubMed ID: 20145183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
